Improving gene transfer in human renal carcinoma cells: Utilization of adenovirus vectors containing chimeric type 5 and type 35 fiber proteins

Acharya,Bishnu; Terao,Shuji; Suzuki,Toru; Naoe,Michio; Hamada,Katsuyuki; Mizuguchi,Hiroyuki; Gotoh,Akinobu

doi:10.3892/etm_00000085

Improving gene transfer in human renal carcinoma cells: Utilization of adenovirus vectors containing chimeric type 5 and type 35 fiber proteins

Authors:
- Bishnu Acharya
- Shuji Terao
- Toru Suzuki
- Michio Naoe
- Katsuyuki Hamada
- Hiroyuki Mizuguchi
- Akinobu Gotoh
View Affiliations

Affiliations: Laboratory of Cell and Gene Therapy, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Hyogo 663-8501, Japan
Published online on: May 1, 2010 https://doi.org/10.3892/etm_00000085
Pages: 537-540

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The transduction efficacy of adenovirus serotype 5 (Ad5) vector in human renal carcinoma cells is generally low due to the down-regulated expression of Coxsackie and adenovirus receptor (CAR) in target cells. By contrast, the infectivity of adenovirus serotype 35 vectors depends on the binding rate to CD46 receptor, independent of CAR. In this study, we examined whether an adenovirus vector containing chimeric type 5 and type 35 fiber proteins (Ad5/F35) increases transduction efficiency compared to Ad5 vector in human renal carcinoma cells in vitro. The expression of CAR was much lower in the human renal carcinoma cells than in control HEK293 cells. By contrast, the expression of CD46 was similar and perhaps at a higher level in the human renal carcinoma cells than in the HEK293 cells. The transduction efficacy of Ad5/F35 vector was dramatically higher compared to that of Ad5 in human renal carcinoma cells, and was correlated to the expression of CD46. Thus, Ad5/35 vector may be useful for the development of novel gene therapy approaches to renal cell carcinoma.

View Figures

View References

1.	American Cancer Society: Cancer Facts and Figures 2009. American Cancer Society; Atlanta: 2009
2.	Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A and Wilt T: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 1:CD0014252005.
3.	Castellano D, Del Muro XG, Pérez-Gracia JL, González-Larriba JL, Abrio MV, Ruiz MA, Pardo A, Guzmán C, Cerezo SD and Grande E: Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Ann Oncol. 20:1803–1812. 2009.PubMed/NCBI
4.	Rini BI, Halabi S, Taylor J, Small EJ and Schilsky RL; Cancer and Leukemia Group B: Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 10:2584–2586. 2004. View Article : Google Scholar
5.	Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX and Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 349:427–434. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Hamilton MM, Byrnes GA, Gall JG, Brough DE, King CR and Wei LL: Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Molecular Vision. 14:2535–2546. 2008.PubMed/NCBI
7.	Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowel RL and Finberg RW: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 275:1320–1323. 1997. View Article : Google Scholar : PubMed/NCBI
8.	Okegawa T, Sayne JR, Nutahara K, Pong RC, Saboorian H, Kabbani W, Higashihara E and Hsieh JT: A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells. J Urol. 177:1148–1156. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Mizuguchi H and Hayakawa T: Targeted adenovirus vectors. Hum Gene Ther. 15:1034–1044. 2004. View Article : Google Scholar
10.	Gaggar A, Shayakhmetov DM and Lieber A: CD46 is a cellular receptor for group B adenoviruses. Nat Med. 9:1408–1412. 2003. View Article : Google Scholar : PubMed/NCBI
11.	Segerman A, Atkinson JP, Marttila M, Dennerquist V, Wadell G and Arnberg N: Adenovirus type 11 uses CD46 as a cellular receptor. J Virol. 77:9183–9191. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Marttila M, Persson D, Gustafsson D, Liszewski MK, Atkinson JP, Wadell G and Arnberg N: CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J Virol. 79:14429–14436. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Toyoda E, Doi R, Kami K, Mori T, Ito D, Koizumi M, Kida A, Nagai K, Ito T, Masui T, Wada M, Tagawa M and Uemoto S: Adenovirus vectors with chimeric type 5 and 35 fiber proteins exhibit enhanced transfection of human pancreatic cancer cells. Int J Oncol. 33:1141–1147. 2008.PubMed/NCBI
14.	Yu L, Shimozato O, Li Q, Kawamura K, Ma G, Namba M, Ogawa T, Kaiho I and Tagawa M: Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and independent manners. Anticancer Res. 27:2311–2316. 2007.PubMed/NCBI
15.	Mizuguchi H and Hayakawa T: Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene. 20:69–77. 2002. View Article : Google Scholar
16.	Ni S, Gaggar A, Di Paolo N, Li ZY, Liu Y, Strauss R, Sova P, Morihara J, Feng Q, Kiviat N, Touré P, Sow PS and Lieber A: Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Ther. 13:1072–1081. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Yu L, Takenobu H, Shimozato O, Kawamura K, Nimura Y, Seki N, Uzawa K, Tanzawa H, Shimada H, Ochiai T and Tagawa M: Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncol Rep. 14:831–835. 2005.PubMed/NCBI
18.	Terao S, Acharya B, Suzuki T, Aoi T, Naoe M, Hamada K, Mizuguchi H and Gotoh A: Improved gene transfer into renal carcinoma cells using adenovirus vector containing RGD motif. Anticancer Res. 29:2997–3002. 2009.PubMed/NCBI
19.	Koizumi N, Mizuguchi H, Kondoh M, Fujii M, Nakanishi T, Utoguchi N and Watanabe Y: Efficient gene transfer into differentiated human trophoblast cells with adenovirus vector containing RGD motif in the fiber protein. Biol Pharm Bull. 29:1297–1299. 2006. View Article : Google Scholar
20.	Wechsel HW, Petri E, Feil G, Nelde HJ, Bichler KH and Loesr W: Renal cell carcinoma: immunohistological investigation of expression of the integrin alpha v beta 3. Anticancer Res. 19:1529–1532. 1999.PubMed/NCBI
21.	Chen L, Chen D, Gong M, Na M, Li L, Wu H, Jiang L, Qian Y, Fang G and Xue X: Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells. Cancer Lett. 284:141–148. 2009. View Article : Google Scholar
22.	Toivonen R, Suominen E, Grenman R and Savontaus M: Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer. Oncol Rep. 21:165–171. 2009.PubMed/NCBI